CoChat

Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1

Open access

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

Significance: NEPC is a highly aggressive subtype of prostate cancer that is increasing in incidence, likely due to use of new secondary androgen deprivation therapies. Here, we demonstrate that Trop2 is significantly elevated in CRPC and NEPC and represents a driver of metastatic NEPC. Trop2 overexpression increases tumor growth, drives metastasis and neuroendocrine phenotype, and significantly increases PARP1 levels. Inhibition of PARP1 in Trop2-driven NEPC significantly decreases neuroendocrine features, tumor growth, and metastatic colonization in vivo, suggesting that PARP1 inhibitors may represent a promising therapeutic strategy for metastatic prostate cancer expressing high levels of Trop2.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1905384117

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Trop2 is elevated in prostate cancer and positively associated with biochemical recurrence and metastatic risk. (A) IHC staining of Trop2 on tissue microarrays (TMAs) composed of normal prostate (n = 26) and prostate cancer Gleason 4+3 (n = 79). Trop2 staining intensity was scored from 0 to 3 (0 is negative, 1 is uninterpretable, 2 is weak positive [low], 3 is strong positive [high]). Representative images for negative and high staining are shown. (Scale bars represent 200 and 25 μm, respectively [enlarged images].) Examples for negative, low, and high Trop2 staining are shown in SI Appendix, Fig. S1. (Right) Represents the distribution of Trop2 intensity scores as a percentage of patient samples. (B) Trop2 IHC on independent TMAs with associated clinical and pathological data. Representative images for Trop2 staining of patient samples with different Gleason scores and recurrence status are shown. (Scale bars represent 200 and 25 μm, respectively [enlarged images in Lower].) (C) Strong staining for Trop2 correlates with prostate cancer recurrence after prostatectomy (recurrent patients, n = 58, and nonrecurrent patients, n = 176). P = 0.01 by log-rank test. (D) Strong Trop2 expression correlates with prostate cancer metastasis. Samples from patients with no metastasis (Non-met) (n = 204) and patients with metastasis (n = 18, including lymph node [LN] [n = 12] and bone metastasis [n = 6]) were used. The statistical significance of the differences between no metastasis and metastasis proportions was calculated by the normal distribution N(0,1) of the z-score. P = 0.02.
Fig. 1. Trop2 is elevated in prostate cancer and positively associated with biochemical recurrence and metastatic risk. (A) IHC staining of Trop2 on tissue microarrays (TMAs) composed of normal prostate (n = 26) and prostate cancer Gleason 4+3 (n = 79). Trop2 staining intensity was scored from 0 to 3 (0 is negative, 1 is uninterpretable, 2 is weak positive [low], 3 is strong positive [high]). Representative images for negative and high staining are shown. (Scale bars represent 200 and 25 μm, respectively [enlarged images].) Examples for negative, low, and high Trop2 staining are shown in SI Appendix, Fig. S1. (Right) Represents the distribution of Trop2 intensity scores as a percentage of patient samples. (B) Trop2 IHC on independent TMAs with associated clinical and pathological data. Representative images for Trop2 staining of patient samples with different Gleason scores and recurrence status are shown. (Scale bars represent 200 and 25 μm, respectively [enlarged images in Lower].) (C) Strong staining for Trop2 correlates with prostate cancer recurrence after prostatectomy (recurrent patients, n = 58, and nonrecurrent patients, n = 176). P = 0.01 by log-rank test. (D) Strong Trop2 expression correlates with prostate cancer metastasis. Samples from patients with no metastasis (Non-met) (n = 204) and patients with metastasis (n = 18, including lymph node [LN] [n = 12] and bone metastasis [n = 6]) were used. The statistical significance of the differences between no metastasis and metastasis proportions was calculated by the normal distribution N(0,1) of the z-score. P = 0.02.CC BY-NC-ND · PubMed Central
Fig. 2. Trop2 regulates prostate cancer cell proliferation and clonogenic ability in vitro and in vivo. (A) Trop2 level was assessed by Western blot in DU145 and LNCaP cells expressing RFP, TROP2 gene deletion (DU145-Trop2-KO), and in cell lines overexpressing Trop2 (DU145-Trop2-OV, LNCaP-Trop2-OV). Trop2 appears as doublets or a smear on Western blot due to glycosylation. (B) Cell proliferation graphed as fold-change (compared to the time of plating, day 0) of DU145-RFP, DU145-Trop-KO, or DU145-Trop2-OV cells. (C) Cell proliferation graphed as fold-change in cell number of LNCaP-RFP or LNCaP-Trop2-OV cells. (D, Upper) Colony formation assays of 500 DU145-RFP, DU145-Trop2-KO, and DU145-Trop2-OV cells grown for 9 d and then fixed and stained with crystal violet. The percentage of colony area per well was quantified using ImageJ and is shown in the right graph. (Scale bar, 1 cm.) (D, Lower) Tumorsphere formation assays for DU145-RFP, DU145-Trop2-KO, and DU145-Trop2-OV cells. The number of tumorspheres per well at day 12 is shown in the Right Graph. (Scale bar: 300 μm.) (E, Upper) Colony formation assays for 500 LNCaP-RFP and LNCaP-Trop2-OV cells. (E, Lower) Representative images of tumorsphere assays for LNCaP-RFP and LNCaP-Trop2-OV at day 15. (Scale bar: 300 μm.) Number of spheres per well is plotted to the Right. All experiments were performed in triplicate. Error bars represent SD. (F–H) The s.c. tumor growth of LNCaP-RFP or LNCaP-Trop2-OV (n = 6) (F), DU145-RFP or DU145-Trop2-OV (n = 8) (G), and DU145 Parental or DU145-Trop2-KO (n = 8) (H) tumors, respectively, grown in intact male NSG mice. A total of 1 × 106 cells were injected per tumor. Tumor weights, tumors, hematoxylin/eosin (H&E)-stained tumor sections, and Trop2 IHC of tumor sections are shown below in all panels. In G and H, tumors were harvested when one of the experiment groups reached 350 mm3 tumor volume on average. (Scale bar for tumor images: 1 cm scale bar for IHC = 50 μm.) Error bars represent SEM. *P < 0.05, **P < 0.01, ***P < 0.005; n.s., not significant; determined by Student’s t test (two-tailed) at each time point.
Fig. 2. Trop2 regulates prostate cancer cell proliferation and clonogenic ability in vitro and in vivo. (A) Trop2 level was assessed by Western blot in DU145 and LNCaP cells expressing RFP, TROP2 gene deletion (DU145-Trop2-KO), and in cell lines overexpressing Trop2 (DU145-Trop2-OV, LNCaP-Trop2-OV). Trop2 appears as doublets or a smear on Western blot due to glycosylation. (B) Cell proliferation graphed as fold-change (compared to the time of plating, day 0) of DU145-RFP, DU145-Trop-KO, or DU145-Trop2-OV cells. (C) Cell proliferation graphed as fold-change in cell number of LNCaP-RFP or LNCaP-Trop2-OV cells. (D, Upper) Colony formation assays of 500 DU145-RFP, DU145-Trop2-KO, and DU145-Trop2-OV cells grown for 9 d and then fixed and stained with crystal violet. The percentage of colony area per well was quantified using ImageJ and is shown in the right graph. (Scale bar, 1 cm.) (D, Lower) Tumorsphere formation assays for DU145-RFP, DU145-Trop2-KO, and DU145-Trop2-OV cells. The number of tumorspheres per well at day 12 is shown in the Right Graph. (Scale bar: 300 μm.) (E, Upper) Colony formation assays for 500 LNCaP-RFP and LNCaP-Trop2-OV cells. (E, Lower) Representative images of tumorsphere assays for LNCaP-RFP and LNCaP-Trop2-OV at day 15. (Scale bar: 300 μm.) Number of spheres per well is plotted to the Right. All experiments were performed in triplicate. Error bars represent SD. (F–H) The s.c. tumor growth of LNCaP-RFP or LNCaP-Trop2-OV (n = 6) (F), DU145-RFP or DU145-Trop2-OV (n = 8) (G), and DU145 Parental or DU145-Trop2-KO (n = 8) (H) tumors, respectively, grown in intact male NSG mice. A total of 1 × 106 cells were injected per tumor. Tumor weights, tumors, hematoxylin/eosin (H&E)-stained tumor sections, and Trop2 IHC of tumor sections are shown below in all panels. In G and H, tumors were harvested when one of the experiment groups reached 350 mm3 tumor volume on average. (Scale bar for tumor images: 1 cm scale bar for IHC = 50 μm.) Error bars represent SEM. *P < 0.05, **P < 0.01, ***P < 0.005; n.s., not significant; determined by Student’s t test (two-tailed) at each time point.CC BY-NC-ND · PubMed Central
Fig. 3. Trop2 regulates migration and invasion in vitro. (A) Transwell chamber assays to assess migration after 20 h incubation of DU145-RFP, DU145-Trop2-KO, and DU145-Trop2-OV cells. Experiments were performed in triplicate, and three images per well were used to quantify stained cells that had migrated. The average number of cells in nine fields (three wells) and percentage of migration were normalized to the DU145-RFP cell counts. One of three independent experiments is shown. (Scale bars: 100 μm.) (B) Wound healing assays for DU145- RFP, DU145-Trop2-KO, and DU145-Trop2-OV cells. Experiments were performed in triplicate, and 10 images were acquired per well at 0, 12, 24, and 36 h. The average of the wound area in three wells at 0 h was assigned 100% and used to quantify changes in wound area over time. Representative images are shown. (Scale bar: 100 μm.) (C) Boyden chamber assays to assess invasion of DU145-RFP, DU145-Trop2-KO, and DU145-Trop2-OV cells into a Matrigel-coated insert membrane after 20 h. Representative experiment. (Scale bar: 100 μm.) (D) Matrigel drop 3D invasion assay using LNCaP-RFP and LNCaP-Trop2-OV cells with control shRNA (shControl) or Trop2 shRNA (shTrop2). Cancer cells (5 × 104) in Matrigel were seeded in a 24-well plate, and drops were imaged at day 0 and day 6 using Celigo imager. The cell migration area outside of the drop was measured. Experiments were performed in triplicate, and the relative invasion ability of cancer cells was normalized to the Trop2-OV group. Orange pseudocolor represents living cells from RFP fluorescent signal of stable clones. (Scale bars: 1 mm and 500 μm [enlarged images].) Error bars represent SD. **P < 0.01 and ***P < 0.005 by Student’s t test.
Fig. 3. Trop2 regulates migration and invasion in vitro. (A) Transwell chamber assays to assess migration after 20 h incubation of DU145-RFP, DU145-Trop2-KO, and DU145-Trop2-OV cells. Experiments were performed in triplicate, and three images per well were used to quantify stained cells that had migrated. The average number of cells in nine fields (three wells) and percentage of migration were normalized to the DU145-RFP cell counts. One of three independent experiments is shown. (Scale bars: 100 μm.) (B) Wound healing assays for DU145- RFP, DU145-Trop2-KO, and DU145-Trop2-OV cells. Experiments were performed in triplicate, and 10 images were acquired per well at 0, 12, 24, and 36 h. The average of the wound area in three wells at 0 h was assigned 100% and used to quantify changes in wound area over time. Representative images are shown. (Scale bar: 100 μm.) (C) Boyden chamber assays to assess invasion of DU145-RFP, DU145-Trop2-KO, and DU145-Trop2-OV cells into a Matrigel-coated insert membrane after 20 h. Representative experiment. (Scale bar: 100 μm.) (D) Matrigel drop 3D invasion assay using LNCaP-RFP and LNCaP-Trop2-OV cells with control shRNA (shControl) or Trop2 shRNA (shTrop2). Cancer cells (5 × 104) in Matrigel were seeded in a 24-well plate, and drops were imaged at day 0 and day 6 using Celigo imager. The cell migration area outside of the drop was measured. Experiments were performed in triplicate, and the relative invasion ability of cancer cells was normalized to the Trop2-OV group. Orange pseudocolor represents living cells from RFP fluorescent signal of stable clones. (Scale bars: 1 mm and 500 μm [enlarged images].) Error bars represent SD. **P < 0.01 and ***P < 0.005 by Student’s t test.CC BY-NC-ND · PubMed Central
Fig. 4. Trop2 drives bone and liver metastasis in vivo. (A) LNCaP-RFP and LNCaP-Trop2-OV cells (1 × 105) expressing luciferase and RFP were injected into the left ventricle of male NSG mice (n = 11 and n = 9). Whole body bioluminescence intensity (BLI) (photons/second/cm2/surface radiance) is shown and quantified at day 21 in Right. Red circles 1 and 2 show the tibiae of experimental animals displayed in B and C. (B) Tibiae metastases were imaged by μCT and reconstructed using maximum-intensity projection (MIP) and volume rendered (VR-3D) 3D techniques. Yellow arrows indicate tumor lesions. (Scale bars of μCT images: 500 μm and 50 μm [enlarged images].) (C) RFP signal representing tibial bone metastasis of LNCaP-Trop2-OV cells (yellow arrowheads). Tibiae and livers were also imaged with dark-field (DF) application in C, D, G, and H. The percentage of mice with bone metastasis is shown in the Right. IHC of bone metastases demonstrates expression of human Trop2. B.M., bone marrow. (Scale bar: 2 mm.) (D) RFP signal of the liver surface for LNCaP-RFP and RFP-labeled LNCaP-Trop2-OV. IHC for human Trop2 is shown in the Middle. (Scale bars: 1 mm, low power, and 250 μm, high power images.) Number and size of liver metastases based on counting of the RFP foci using ImageJ are shown at Right. (E) Bioluminescence activity 21 d after intracardiac injection of 1 × 105 luciferase-labeled DU145-RFP, DU145-Trop2-KO, and DU145-Trop2-OV cells in male NSG mice (n = 5 to 6). Red circles 3, 4, and 5 indicate the tibiae of the same experimental animals displayed in F and G. BLI is shown graphically on the Right. (F) Volume rendered μCT images of tibial lesions (indicated by the yellow arrows) of the DU145-derived cell lines. (Scale bars of μCT images: 500 μm and 50 μm [enlarged images].) (G) Fluorescence microscopy of harvested hind limbs for RFP demonstrating bone metastases indicated by the yellow arrowheads. (Scale bars: 2 mm.) The percentage of mice with bone metastasis is quantified in the Right. (H) Liver lesions in the DU145-derived cell lines displayed in D imaged for surface RFP expression, and sliced FFPE tissues stained for hTrop2 IHC. Number of metastatic foci and size of foci quantified in Right. Error bars depict SEM. (Scale bars: 1 mm, low power, and 250 μm, high power images.) *P < 0.05, **P < 0.01, ***P < 0.005; n.s., not significant.
Fig. 4. Trop2 drives bone and liver metastasis in vivo. (A) LNCaP-RFP and LNCaP-Trop2-OV cells (1 × 105) expressing luciferase and RFP were injected into the left ventricle of male NSG mice (n = 11 and n = 9). Whole body bioluminescence intensity (BLI) (photons/second/cm2/surface radiance) is shown and quantified at day 21 in Right. Red circles 1 and 2 show the tibiae of experimental animals displayed in B and C. (B) Tibiae metastases were imaged by μCT and reconstructed using maximum-intensity projection (MIP) and volume rendered (VR-3D) 3D techniques. Yellow arrows indicate tumor lesions. (Scale bars of μCT images: 500 μm and 50 μm [enlarged images].) (C) RFP signal representing tibial bone metastasis of LNCaP-Trop2-OV cells (yellow arrowheads). Tibiae and livers were also imaged with dark-field (DF) application in C, D, G, and H. The percentage of mice with bone metastasis is shown in the Right. IHC of bone metastases demonstrates expression of human Trop2. B.M., bone marrow. (Scale bar: 2 mm.) (D) RFP signal of the liver surface for LNCaP-RFP and RFP-labeled LNCaP-Trop2-OV. IHC for human Trop2 is shown in the Middle. (Scale bars: 1 mm, low power, and 250 μm, high power images.) Number and size of liver metastases based on counting of the RFP foci using ImageJ are shown at Right. (E) Bioluminescence activity 21 d after intracardiac injection of 1 × 105 luciferase-labeled DU145-RFP, DU145-Trop2-KO, and DU145-Trop2-OV cells in male NSG mice (n = 5 to 6). Red circles 3, 4, and 5 indicate the tibiae of the same experimental animals displayed in F and G. BLI is shown graphically on the Right. (F) Volume rendered μCT images of tibial lesions (indicated by the yellow arrows) of the DU145-derived cell lines. (Scale bars of μCT images: 500 μm and 50 μm [enlarged images].) (G) Fluorescence microscopy of harvested hind limbs for RFP demonstrating bone metastases indicated by the yellow arrowheads. (Scale bars: 2 mm.) The percentage of mice with bone metastasis is quantified in the Right. (H) Liver lesions in the DU145-derived cell lines displayed in D imaged for surface RFP expression, and sliced FFPE tissues stained for hTrop2 IHC. Number of metastatic foci and size of foci quantified in Right. Error bars depict SEM. (Scale bars: 1 mm, low power, and 250 μm, high power images.) *P < 0.05, **P < 0.01, ***P < 0.005; n.s., not significant.CC BY-NC-ND · PubMed Central
Fig. 5. Tumors driven by Trop2 exhibit neuroendocrine features and high levels of PARP1. (A) Heat map displaying fold change of 121 up-regulated and 125 down-regulated proteins in two independent LNCaP-Trop2-OV tumor xenografts and LNCaP-RFP control tumors assessed by mass spectrometry-based shotgun proteomics. In LNCaP-Trop2-OV tumors, PARP1 is the most highly up-regulated protein, and the AR target PSA is significantly repressed. Previously identified androgen responsive genes (ARG) are labeled in green. (B) Volcano plot of the Trop2-regulated candidates with the dotted lines representing P value < 0.01 and fold change > eightfold. (C) Functional protein association networks for Trop2 up-regulated proteins (n = 121) were analyzed using STRING (https://string-db.org/). The red node indicates a cluster of proteins related to chromosome organization (n = 18). Four major functional groups (clusters) including RNA splicing (blue), translation (purple), protein folding (green), DNA replication, and chromosome organization (red) are indicated. Line thickness indicates the strength of data support of correlation between each node. (D) Western blot for Trop2, AR, PSA (AR and AR targets in blue), PSMA (in black), PARP1 (in orange), CD56, SYP (neuroendocrine markers in purple), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (loading control) in the LNCaP-RFP and LNCaP-Trop2-OV tumor lysates used for proteomic analysis. (E) H&E and IHC staining for Trop2, AR, PSA, PSMA, PARP1, CD56, SYP, and CHGA in LNCaP-RFP and LNCaP-Trop2-OV tumors. (Scale bars: 50 μm.) (F) Western blot for AR, CD56, SYP, SOX2, EZH2, and GAPDH in LNCaP-RFP and LNCaP-Trop2-OV cells. (G) Staining intensity of Trop2 in localized prostate cancer (localized PC) (n = 12), CRPC (n = 9), and NEPC (n = 23). (Scale bars: 200 μm, low power; and 50 μm, high power.) Distribution of Trop2 staining intensity of prostate tumor samples is shown in the Right. The statistical significance of the differences between localized PC, CRPC, and NEPC proportions was calculated by the normal distribution (0,1) of the z-score.
Fig. 5. Tumors driven by Trop2 exhibit neuroendocrine features and high levels of PARP1. (A) Heat map displaying fold change of 121 up-regulated and 125 down-regulated proteins in two independent LNCaP-Trop2-OV tumor xenografts and LNCaP-RFP control tumors assessed by mass spectrometry-based shotgun proteomics. In LNCaP-Trop2-OV tumors, PARP1 is the most highly up-regulated protein, and the AR target PSA is significantly repressed. Previously identified androgen responsive genes (ARG) are labeled in green. (B) Volcano plot of the Trop2-regulated candidates with the dotted lines representing P value < 0.01 and fold change > eightfold. (C) Functional protein association networks for Trop2 up-regulated proteins (n = 121) were analyzed using STRING (https://string-db.org/). The red node indicates a cluster of proteins related to chromosome organization (n = 18). Four major functional groups (clusters) including RNA splicing (blue), translation (purple), protein folding (green), DNA replication, and chromosome organization (red) are indicated. Line thickness indicates the strength of data support of correlation between each node. (D) Western blot for Trop2, AR, PSA (AR and AR targets in blue), PSMA (in black), PARP1 (in orange), CD56, SYP (neuroendocrine markers in purple), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (loading control) in the LNCaP-RFP and LNCaP-Trop2-OV tumor lysates used for proteomic analysis. (E) H&E and IHC staining for Trop2, AR, PSA, PSMA, PARP1, CD56, SYP, and CHGA in LNCaP-RFP and LNCaP-Trop2-OV tumors. (Scale bars: 50 μm.) (F) Western blot for AR, CD56, SYP, SOX2, EZH2, and GAPDH in LNCaP-RFP and LNCaP-Trop2-OV cells. (G) Staining intensity of Trop2 in localized prostate cancer (localized PC) (n = 12), CRPC (n = 9), and NEPC (n = 23). (Scale bars: 200 μm, low power; and 50 μm, high power.) Distribution of Trop2 staining intensity of prostate tumor samples is shown in the Right. The statistical significance of the differences between localized PC, CRPC, and NEPC proportions was calculated by the normal distribution (0,1) of the z-score.CC BY-NC-ND · PubMed Central
Fig. 6. Trop2-overexpressing cells and tumors are insensitive to androgen ablation in vitro and in vivo. (A) Proliferation of LNCaP-RFP and LNCaP-Trop2-OV grown in RPMI (RPMI 1640 medium) supplemented with androgen replete FBS or charcoal stripped FBS (csFBS), which is depleted of androgens. The medium was replaced every 2 d. Cell proliferation is plotted as percentage increase (fold-change) compared to day 0. Bars represent SD. One of three independent experiments is shown. (B) Cell proliferation of LNCaP-RFP and LNCaP-Trop2-OV upon treatment with vehicle, dimethyl sulfoxide (DMSO), or enzalutamide (5 µM) is plotted as fold-change compared to day 0. Error bars = SD. (C) Tumorsphere assay of LNCaP-RFP and LNCaP-Trop2-OV-RFP cells grown in either 10% FBS or 10% csFBS containing RPMI. The number of tumorspheres per well was counted at day 21 (LNCaP-RFP) and day 15 (LNCaP-Trop2-OV) based on RFP signal using ImageJ. (Scale bars: 300 μm.) The experiment was performed in triplicate, and representative images are shown. Error bars = SD. (D) Growth of xenografts of LNCaP-RFP or LNCaP-Trop2-OV in intact or castrated recipient male NSG mice (n = 8 to 10 tumors per experimental group). Tumor weight and harvested tumors are shown Below (Scale bar: 1 cm.). Human Trop2 expression by IHC is shown at the Bottom (Scale bars: 50 μm.). Error bars represent SEM. *P < 0.05, **P < 0.01, ***P < 0.005; n.s., not significant; as determined by Student’s t test at each measurement point.
Fig. 6. Trop2-overexpressing cells and tumors are insensitive to androgen ablation in vitro and in vivo. (A) Proliferation of LNCaP-RFP and LNCaP-Trop2-OV grown in RPMI (RPMI 1640 medium) supplemented with androgen replete FBS or charcoal stripped FBS (csFBS), which is depleted of androgens. The medium was replaced every 2 d. Cell proliferation is plotted as percentage increase (fold-change) compared to day 0. Bars represent SD. One of three independent experiments is shown. (B) Cell proliferation of LNCaP-RFP and LNCaP-Trop2-OV upon treatment with vehicle, dimethyl sulfoxide (DMSO), or enzalutamide (5 µM) is plotted as fold-change compared to day 0. Error bars = SD. (C) Tumorsphere assay of LNCaP-RFP and LNCaP-Trop2-OV-RFP cells grown in either 10% FBS or 10% csFBS containing RPMI. The number of tumorspheres per well was counted at day 21 (LNCaP-RFP) and day 15 (LNCaP-Trop2-OV) based on RFP signal using ImageJ. (Scale bars: 300 μm.) The experiment was performed in triplicate, and representative images are shown. Error bars = SD. (D) Growth of xenografts of LNCaP-RFP or LNCaP-Trop2-OV in intact or castrated recipient male NSG mice (n = 8 to 10 tumors per experimental group). Tumor weight and harvested tumors are shown Below (Scale bar: 1 cm.). Human Trop2 expression by IHC is shown at the Bottom (Scale bars: 50 μm.). Error bars represent SEM. *P < 0.05, **P < 0.01, ***P < 0.005; n.s., not significant; as determined by Student’s t test at each measurement point.CC BY-NC-ND · PubMed Central
Fig. 7. Targeting PARP1 enzyme activity in Trop2-driven NEPC suppresses tumor growth, bone metastasis, and reverses Trop2-induced NEPC phenotype. (A) Western blot of Trop2 and PARP1 proteins in LNCaP-RFP and LNCaP-Trop2-OV. (B) Immunocytochemistry and confocal imaging for Trop2, and PARP1 enzyme activity (PARylation) in paraformaldehyde-fixed LNCaP-RFP and LNCaP-Trop2-OV cells treated with DMSO control, talazoparib (10 nM) or olaparib (10 μM) for 3 d. (Scale bars: 10 μm.) (C) Colony formation assays of LNCaP-RFP or LNCaP-Trop2-OV cells treated with talazoparib (0–25 nM) or olaparib (0–5 µM). At day 9, the colonies were fixed and stained with crystal violet, and the percentage of colony area per well is plotted as percent colony formation relative to the Trop2-OV treated with vehicle. (D) Growth of LNCaP-Trop2-OV s.c. xenografts treated daily with talazoparib (0.5 mg/kg) or olaparib (50 mg/kg), injected i.p. (tumor n = 7 to 11 per experimental group). (E) IHC staining for Trop2, PARP1, and PARP1 enzyme activity (PARylation), and three neuroendocrine markers (CD56, SYP, and CHGA) in LNCaP-Trop2-OV tumor xenografts treated with vehicle (veh), talazoparib (Tala) or olaparib (Ola) or LNCaP-RFP control with vehicle or olaparib. (Scale bars: 50 μm.) (F) Matrigel drop invasion assays of LNCaP-RFP or LNCaP-Trop2-OV cells treated with talazoparib or olaparib. Representative images of invading edge of the whole Matrigel drop (Upper) and enlarged image (Lower) are shown. The percentage of relative invading area per drop is shown in the Right Graph. (Scale bars: 1 mm [Upper] and 200 μm [Lower].) (G) Olaparib decreases metastasis of LNCaP-Trop2-OV cells in an intracardiac injection model. Olaparib (50 mg/kg) or vehicle control began 3 d after intracardiac injection with imaging at 7 and 14 d (see Insert of study design). BLI of mice at day 0 and day 14 of control (Ctl) and olaparib-treated animals is shown at Left, and whole body quantified BLI is shown at the Bottom Right. Percentage of mice with tibial bone metastasis in control and olaparib-treated mice is shown at Bottom Right. Error bars represent SD, and in vivo panels error bar = SEM. *P value < 0.05, **P value < 0.01, and ***P value < 0.005, assessed by Student’s t test.
Fig. 7. Targeting PARP1 enzyme activity in Trop2-driven NEPC suppresses tumor growth, bone metastasis, and reverses Trop2-induced NEPC phenotype. (A) Western blot of Trop2 and PARP1 proteins in LNCaP-RFP and LNCaP-Trop2-OV. (B) Immunocytochemistry and confocal imaging for Trop2, and PARP1 enzyme activity (PARylation) in paraformaldehyde-fixed LNCaP-RFP and LNCaP-Trop2-OV cells treated with DMSO control, talazoparib (10 nM) or olaparib (10 μM) for 3 d. (Scale bars: 10 μm.) (C) Colony formation assays of LNCaP-RFP or LNCaP-Trop2-OV cells treated with talazoparib (0–25 nM) or olaparib (0–5 µM). At day 9, the colonies were fixed and stained with crystal violet, and the percentage of colony area per well is plotted as percent colony formation relative to the Trop2-OV treated with vehicle. (D) Growth of LNCaP-Trop2-OV s.c. xenografts treated daily with talazoparib (0.5 mg/kg) or olaparib (50 mg/kg), injected i.p. (tumor n = 7 to 11 per experimental group). (E) IHC staining for Trop2, PARP1, and PARP1 enzyme activity (PARylation), and three neuroendocrine markers (CD56, SYP, and CHGA) in LNCaP-Trop2-OV tumor xenografts treated with vehicle (veh), talazoparib (Tala) or olaparib (Ola) or LNCaP-RFP control with vehicle or olaparib. (Scale bars: 50 μm.) (F) Matrigel drop invasion assays of LNCaP-RFP or LNCaP-Trop2-OV cells treated with talazoparib or olaparib. Representative images of invading edge of the whole Matrigel drop (Upper) and enlarged image (Lower) are shown. The percentage of relative invading area per drop is shown in the Right Graph. (Scale bars: 1 mm [Upper] and 200 μm [Lower].) (G) Olaparib decreases metastasis of LNCaP-Trop2-OV cells in an intracardiac injection model. Olaparib (50 mg/kg) or vehicle control began 3 d after intracardiac injection with imaging at 7 and 14 d (see Insert of study design). BLI of mice at day 0 and day 14 of control (Ctl) and olaparib-treated animals is shown at Left, and whole body quantified BLI is shown at the Bottom Right. Percentage of mice with tibial bone metastasis in control and olaparib-treated mice is shown at Bottom Right. Error bars represent SD, and in vivo panels error bar = SEM. *P value < 0.05, **P value < 0.01, and ***P value < 0.005, assessed by Student’s t test.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

See all 155

Metadata

Authors
Hsu, E.-C., Rice, M. A., Bermudez, A., Marques, F. J. G., Aslan, M., Liu, S., Ghoochani, A., Zhang, C. A., Chen, Y.-S., Zlitni, A., Kumar, S., Nolley, R., Habte, F., Shen, M., Koul, K., Peehl, D. M., Zoubeidi, A., Gambhir, S. S., Kunder, C. A., Pitteri, S. J., Brooks, J. D., & Stoyanova, T.
Affiliations
  • Stanford Medicine (US)
  • Department of Radiology, Stanford University, Stanford, CA 94304;
  • University of British Columbia (CA)
  • University of California, San Francisco (US)
Corresponding author
Stoyanova, Tanya
Venue
Proceedings of the National Academy of Sciences
Published
2020-01-13
Volume
117
Issue
4
Pages
2032-2042
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2999659032
Cited by
146
References
46
Citations by year
2026: 14 · 2025: 22 · 2024: 19 · 2023: 28 · 2022: 30 · 2021: 25 · 2020: 8
FWCI
12.81
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
Funders
  • NIH (R03CA230819)
  • DOD PCRP (W81XWH1810323, W81XWH1810141)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords
TROP2, neuroendocrine prostate cancer, castration-resistant prostate cancer, PARP1, PARP inhibitors, metastasis, androgen deprivation therapy resistance, tumor recurrence, therapeutic target, tumor growth
MeSH terms
Poly(ADP-ribose) Polymerase Inhibitors, Poly (ADP-Ribose) Polymerase-1, Animals, Antigens, Neoplasm, Bone Neoplasms, Cell Movement, Follow-Up Studies, Humans, Male, Neoplasm Invasiveness, Phenotype, Prognosis, Tumor Cells, Cultured, Biomarkers, Tumor, Cell Adhesion Molecules, Gene Expression Regulation, Neoplastic, Survival Rate, Mice, SCID, Mice, Inbred NOD, Apoptosis, Carcinoma, Neuroendocrine, Xenograft Model Antitumor Assays, Cell Proliferation, Mice, Prostatic Neoplasms, Castration-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. https://app.cochat.ai/papers/10.1073/pnas.1905384117
The paper
Hsu, E.-C., Rice, M. A., Bermudez, A., Marques, F. J. G., Aslan, M., Liu, S., Ghoochani, A., Zhang, C. A., Chen, Y.-S., Zlitni, A., Kumar, S., Nolley, R., Habte, F., Shen, M., Koul, K., Peehl, D. M., Zoubeidi, A., Gambhir, S. S., Kunder, C. A., . . . Stoyanova, T. (2020). Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1905384117

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.